Genistein inhibits expression of vascular endothelial growth factor in HER-2/neu transfected human breast cancer MCF-7 cells
- 42 Downloads
- 1 Citations
Abstract
Objective
our previous studies have demonstrated that HER-2/neu gene expression in human breast cancer MCF-7 cells promotes angiogenesis in MCF-7 cells xenograft tumors, and genistein inhibits angiogenesis in MCF-7 cells with HER-2/neu expression xenograft tumors. Here, the effects of genistein on the expression of vascular endothelial growth factor (VEGF) in MCR-7 cells with HER-2/neu expression were further studied for exploring the molecular mechanism of anti-angiogenesis in HER-2/neu-overexpressing breast cancer by genistein.
Methods
HER-2/neu-overexpressing MCF-7 cells (MCF-7/HER-2) were established by transfecting HER-2/neu gene into HER-2/neu negative expression breast cancer MCF-7 cells. Immunocytochemical staining, western blot and reverse transcription-polymerase chain reaction (RT-PCR) were adopted to measure the expression of VEGF in MCF-7/HER-2 cells treated by genistein for 24, 48 and 72h.
Results
HER-2/neu expression up-regulated VEGF mRNA and protein in MCF-7 cells, genistein decreased VEGF mRNA and protein level in MCF-7/HER-2 cells in a time-dependent manner.
Conclusion
These results suggest that VEGF plays an important role in HER-2/neu gene expression promoted antiogenesis in breast cancer and genistein induced down-regulation of the expression of VEGF may be one of the molecular mechanisms of its anti-angiogenesis in HER-2/neu-overexpressing breast cancer.
Key words
Genistein Vascular endothelial growth factor HER-2/neu Breast cancerCLC number
R737.9Preview
Unable to display preview. Download preview PDF.
References
- [1]Zetter BR. Angiogenesis and metastasis[J]. Ann Rev Med 1998; 49: 407–24.PubMedCrossRefGoogle Scholar
- [2]McNamara DA, Harmey JH, Walsh TN, et al. Significance of angiogenesis in cancer therapy[J]. Br J Surg 1998; 85: 1044–5.PubMedCrossRefGoogle Scholar
- [3]Marme D. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor[J]. World J Urol 1996; 14: 166–74.PubMedCrossRefGoogle Scholar
- [4]Toikkanen S, Helin H, Isola J, et al. prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up[J]. J Clin Oncol 1992; 10: 1044–8.PubMedGoogle Scholar
- [5]Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endotherlial growth factor secretion in cancer cells and stimulates angiogenesis[J]. Oncogene 2000; 19: 3460–9.PubMedCrossRefGoogle Scholar
- [6]Epstein M, Ayala R, Tchekmedyian N, et al. HER-2/neu-overexpssing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF)[J]. Breast Cancer Res Treat 2002; 76(S1): S143.Google Scholar
- [7]Izumi Y, Xu L, di Tomaso E, et al. Tumor biology: herceptin acts as an anti-angiogenic cocktail[J]. Nature 2002; 416: 279–80.PubMedCrossRefGoogle Scholar
- [8]Zhu JD, Yu XP, Mi MT. Inhibitory effect of genistein on the angiogenesis in HER-2/neu-overexpressing breast cancer xenograft in nude mice[J]. Chin J Clin Rehab 2005; 9: 228–30.Google Scholar
- [9]Etoh T, Inoue H, Tanaka S, et al. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases[J]. Cancer Res 2001; 61: 2145–53.PubMedGoogle Scholar
- [10]Weidner N, Semple JP, Welch JR, et al. Tumorangiogenesis and metastasis-correlation in invasive breast carcinoma[J]. N Engl J Med 1991; 324: 1–8.PubMedCrossRefGoogle Scholar
- [11]Kern FG, Lippman ME. The role of angiogenic growth factors in breast cancer progression[J]. Cancer Metastasis Rev 1996; 15: 213–9.PubMedCrossRefGoogle Scholar
- [12]Margolin K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors[J]. Curr Oncol Rep 2002; 4: 20–8.PubMedGoogle Scholar
- [13]Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis[J]. Nature 1992; 359: 843–5.PubMedCrossRefGoogle Scholar
- [14]Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor[J]. Endocr Rev 1997; 18: 4–25.PubMedCrossRefGoogle Scholar
- [15]Linderholm BK, Lindahl T, Holmberg L, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer[J]. Cancer Res 2001; 61: 2256–60.PubMedGoogle Scholar
- [16]Jiang BH, Agani F, Passaniti A, et al. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression[J]. Cancer Res 1997; 57: 5328–35.PubMedGoogle Scholar
- [17]Liu W, Li J, Rothe RA. Heregulin regulation of Akt/protein kinase B in breast cancer cells[J]. Biochem Biophys Res Communication 1999; 261: 897–903.CrossRefGoogle Scholar
- [18]Konecny GE Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients[J]. Clin Cancer Res 2004; 10: 1706–16.PubMedCrossRefGoogle Scholar
- [19]Laughner E, Taghavi P, chiles K, et al. HER-2/neu signaling increases the rate of hypoxia-inducible factor 1 α (HIF-1 α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression[J]. Mol Cell Biol 2001; 21: 3995–4004.PubMedCrossRefGoogle Scholar
- [20]Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases[J]. J Biol Chem 1987; 262: 5592–5.PubMedGoogle Scholar